Procarta Biosystems

is developing a new class of DNA-based therapeuticals,

snare™

antibacterials, capable of combating drug-resistant bacterial infections.

snare™

antibacterials act on novel genomic targets by capturing key regulatory proteins to block essential bacterial genes and defeat infection.

Procarta is creating an extensive pipeline to tackle some of the most challenging bacterial infections in the clinic. The WHO is predicting a forthcoming 'disaster due to the rapid, unchecked increase in antimicrobial resistance' largely as a consequence of the paucity of new classes of antibacterials in development.

The proprietary technology platform underlying

snare™

is highly adaptable and can be tuned to meet both current and future clinical needs. As such,

snare™

antibacterials are being developed as agents of first resort to treat today's drug-resistant superbugs.